Market closed
Emergent BioSolutions/$EBS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Ticker
$EBS
Sector
Trading on
NYSE
Industry
Biotechnology
Headquarters
Employees
1,600
Website
EBS Metrics
BasicAdvanced
$540M
Market cap
-
P/E ratio
-$3.98
EPS
1.57
Beta
-
Dividend rate
Price and volume
Market cap
$540M
Beta
1.57
52-week high
$15.10
52-week low
$1.42
Average daily volume
1.4M
Financial strength
Current ratio
2.877
Quick ratio
1.18
Long term debt to equity
130.173
Total debt to equity
130.33
Interest coverage (TTM)
-1.46%
Management effectiveness
Return on assets (TTM)
-4.22%
Return on equity (TTM)
-34.64%
Valuation
Price to revenue (TTM)
0.465
Price to book
1.06
Price to tangible book (TTM)
-57.38
Price to free cash flow (TTM)
3.788
Growth
Revenue change (TTM)
2.05%
Earnings per share change (TTM)
-74.11%
3-year revenue growth (CAGR)
-12.02%
3-year earnings per share growth (CAGR)
-1.67%
What the Analysts think about EBS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
EBS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EBS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EBS News
AllArticlesVideos
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Seeking Alpha·7 days ago
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
Benzinga·1 week ago
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Emergent BioSolutions stock?
Emergent BioSolutions (EBS) has a market cap of $540M as of November 15, 2024.
What is the P/E ratio for Emergent BioSolutions stock?
The price to earnings (P/E) ratio for Emergent BioSolutions (EBS) stock is 0 as of November 15, 2024.
Does Emergent BioSolutions stock pay dividends?
No, Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders as of November 15, 2024.
When is the next Emergent BioSolutions dividend payment date?
Emergent BioSolutions (EBS) stock does not pay dividends to its shareholders.
What is the beta indicator for Emergent BioSolutions?
Emergent BioSolutions (EBS) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.